Armata Pharmaceuticals (ARMP)
(Delayed Data from AMEX)
$2.40 USD
+0.17 (7.62%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $2.37 -0.03 (-1.25%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Income Statements
Fiscal Year end for Armata Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 5 | 6 | 4 | 1 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 5 | 6 | 4 | 1 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 45 | 42 | 28 | 22 | 20 |
Income After Depreciation & Amortization | -41 | -37 | -24 | -22 | -20 |
Non-Operating Income | -26 | 0 | 1 | 0 | 1 |
Interest Expense | 3 | 0 | 0 | 1 | 1 |
Pretax Income | -69 | -37 | -23 | -22 | -19 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -69 | -37 | -23 | -22 | -19 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -69 | -37 | -23 | -22 | -19 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -40 | -36 | -23 | -20 | -18 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 1 | 1 | 1 |
Income After Depreciation & Amortization | -41 | -37 | -24 | -22 | -20 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 36.08 | 34.29 | 24.10 | 16.42 | 8.01 |
Diluted EPS Before Non-Recurring Items | -1.91 | -1.08 | -0.96 | -1.35 | -2.55 |
Diluted Net EPS (GAAP) | -1.91 | -1.08 | -0.96 | -1.35 | -2.55 |
Fiscal Year end for Armata Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.97 | 1.53 | 1.23 | 0.98 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.97 | 1.53 | 1.23 | 0.98 |
SG&A, R&D, and Dept/Amort Expenses | 11.92 | 11.20 | 11.11 | 11.56 | 10.61 |
Income After SG&A, R&D, and Dept/Amort Expenses | -11.92 | -10.23 | -9.58 | -10.33 | -9.63 |
Non-Operating Income | 23.62 | -12.97 | -8.82 | -19.65 | 6.08 |
Interest Expense | 2.72 | 1.82 | 1.45 | 1.18 | 0.00 |
Pretax Income | 8.99 | -25.02 | -19.85 | -31.16 | -3.55 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 8.99 | -25.02 | -19.85 | -31.16 | -3.55 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 8.99 | -25.02 | -19.85 | -31.16 | -3.55 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 58.25 | 36.13 | 36.10 | 36.09 | 56.55 |
Diluted EPS Before Non-Recurring Items | -0.65 | -0.69 | -0.55 | -0.31 | -0.28 |
Diluted Net EPS (GAAP) | 0.25 | -0.69 | -0.48 | -0.86 | -0.17 |